CN106389479B - Application of bacillus coagulans in preparation of preparation for preventing or treating autism - Google Patents
Application of bacillus coagulans in preparation of preparation for preventing or treating autism Download PDFInfo
- Publication number
- CN106389479B CN106389479B CN201611060351.7A CN201611060351A CN106389479B CN 106389479 B CN106389479 B CN 106389479B CN 201611060351 A CN201611060351 A CN 201611060351A CN 106389479 B CN106389479 B CN 106389479B
- Authority
- CN
- China
- Prior art keywords
- bacillus coagulans
- preparation
- autism
- cfu
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000193749 Bacillus coagulans Species 0.000 title claims abstract description 108
- 229940054340 bacillus coagulans Drugs 0.000 title claims abstract description 108
- 238000002360 preparation method Methods 0.000 title claims abstract description 60
- 206010003805 Autism Diseases 0.000 title claims abstract description 43
- 208000020706 Autistic disease Diseases 0.000 title claims abstract description 43
- 208000024891 symptom Diseases 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 21
- 241000186000 Bifidobacterium Species 0.000 description 19
- 239000000843 powder Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 14
- 238000004321 preservation Methods 0.000 description 14
- 230000011273 social behavior Effects 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 230000003321 amplification Effects 0.000 description 8
- 230000006399 behavior Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000003542 behavioural effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000007087 memory ability Effects 0.000 description 7
- 230000003997 social interaction Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000003989 repetitive behavior Effects 0.000 description 2
- 208000013406 repetitive behavior Diseases 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000028752 abnormal posture Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of bacillus coagulans in preparation of preparations for preventing or treating autism, and particularly relates to application of bacillus coagulans in prevention or treatment of autism and reduction of autism symptoms.
Description
Technical Field
The invention relates to application of bacillus coagulans in preparation of preparations for preventing or treating autism, in particular to application of bacillus coagulans in preventing or treating autism and reducing autism symptoms.
Background
Autism, also known as autism, is a developmental disorder disease that is characterized by three major types of core symptoms, namely: social interaction disorder, communication disorder, narrow interests and stereotypical repetitive behavior patterns, about 3/4 with mental retardation in infants. The disease course can last for a lifetime, is difficult to reverse, and the prevalence rate is increased year by year, thus causing huge economic and social burden to families and society. According to the statistics of the world health organization, the number of autistic children in continental China is about 60-180 ten thousand, and students consider that the actual number can reach 260-800 ten thousand. Autism has become an important disease causing mental disability in children, and with the rise of morbidity, enormous social and economic burden is being brought to families and society continuously.
The current treatment measures of the autism mainly comprise behavior intervention and drug intervention, training behavior intervention and psychological cognition treatment are mostly adopted clinically, and drugs are used for symptomatic treatment of accompanying mental symptoms. However, drug (e.g., risperidone, aripiprazole, etc.) intervention often causes various adverse reactions that affect patient treatment compliance and long-term maintenance of treatment. Autistic patients have weak self-control ability and are sensitive to adverse reactions, so the curative effect and safety of the medicine are particularly important for the treatment compliance and long-term maintenance of the treatment of the patients. Therefore, the search for a safe and effective drug for preventing or treating autism and reducing the symptoms of autism is a critical clinical need. The inventor finds that the bacillus coagulans can effectively prevent or treat autism, is safe, does not have any toxic or side effect, has an effect superior to that of bifidobacterium, does not see related research reports, and specially applies for the invention patent.
Disclosure of Invention
The invention aims to provide a preparation capable of preventing or treating autism, which is prepared from bacillus coagulans.
The preparation of the formulation of the present invention is preferably carried out by the following steps, but not limited to this preparation process, and known realizable preparation processes may be used: taking a sample possibly containing bacillus coagulans, then placing the sample in a sterilization bottle, taking a certain amount of sample from the sample during research, adding the sample into 18mL of sterilized diluent, fully mixing the sample and the diluent, and performing 10 times in a sterile operating platform-1、10-2、10-3、10-4、10-5、10-6、10-7Diluting with gradient, taking 10-5、10-6、10-7And (3) respectively coating the three dilution gradients on a bacillus coagulans selective single colony separation solid culture medium, placing the bacillus coagulans selective single colony separation solid culture medium on an incubator, culturing for 48 hours at 37 ℃, respectively inoculating single colonies with good growth vigor into a liquid amplification culture medium, placing the liquid amplification culture medium in the incubator, and performing amplification culture for 48 hours at 37 ℃. Centrifuging the obtained culture solution (12000rpm) to separate thallus, freeze vacuum drying thallus to obtain dry powder, identifying Bacillus coagulans and performing toxicity test according to Berger' S Manual of bacteria identification, related bacteria identification literature or 16S rRNA sequence comparison analysis, adding adjuvants into the nontoxic Bacillus coagulans dry powder according to required proportion, and making into tablet, capsule, powder or liquid preparation, or adding other live bacteria or oligosaccharide such as fructo-oligosaccharide to achieve synergistic effect.
The bacillus coagulans selective single colony isolation solid medium is preferably but not limited to: 1000mL of purified water, 10g of peptone, 10g of beef extract, 2g of diammonium citrate, 5g of sodium acetate, 5g of yeast powder, 5g of glucose, 2g of monopotassium phosphate, 801.0 mL of tween, 20g of calcium carbonate, 0.58g of magnesium sulfate, 0.25g of manganese sulfate and 15g of agar, adjusting the pH value to 6.2-6.5, and autoclaving at 115 ℃ for 20 min.
The bacillus coagulans liquid amplification medium is preferably, but not limited to: 1000mL of purified water, 10g of peptone, 3g of beef extract, 5g of sodium chloride and 5g of glucose, adjusting the pH value to 7, and carrying out autoclaving at 115 ℃ for 20 min.
To further illustrate the present invention in detail, the inventors isolated and identified non-toxic Bacillus coagulans by the above method through a selective single colony isolation solid medium of Bacillus coagulans, which is not limited to the bacteria described for the purpose of illustrating the present invention, and is within the scope of the present invention as long as non-toxic Bacillus coagulans is described in the present invention.
The bacillus coagulans is preferably but not limited to bacillus coagulans TBC169 preservation number CGMCC1207 or bacillus coagulans preservation number CGMCC 1.2407.
Bacteriological Properties of Bacillus coagulans preferably used in the description of the present invention:
1. for the purpose of illustrating the invention, the bacillus coagulans separated by the method is bacillus coagulans TBC169 with the preservation number of CGMCC 1207.
2. Colony morphology
And (4) microscopic observation: rod-like, gram-positive.
Plate form: the colony is white and round, has neat edges and 2-3mm size.
3. Physiological and biochemical identification
Liquefaction of gelatin: -; catalase: +; VP test: +; phenylalanine deaminase assay-.
4. Glycolysis experimental identification
Glucose: +; maltose: +; sucrose: +; xylose: -; fructose: +; rhamnose: -; lactose: +; inulin: +; galactose: +; dextrin: +.
5. The isolated bacteria were subjected to 16S rRNA gene sequencing, the determined sequences were subjected to similarity analysis with gene sequences in GenBank and RDP databases using BLAST, and the isolated bacteria were determined to be Bacillus coagulans.
The bacillus coagulans refers to a living organism individual.
The bacillus coagulans separated by the method with effective dose is taken as a main active ingredient, and conventional excipients, flavoring agents, disintegrating agents, preservatives, lubricants, wetting agents, adhesives, solvents, thickening agents, solubilizing agents and other auxiliary materials are added according to a certain preparation process to prepare any preparation formulation suitable for use, such as tablets, capsules, granules, powder, liquid preparations, powder and other formulations.
The bacillus coagulans is used as a main active pharmaceutical ingredient to prepare a live bacterial preparation.
The effective dose of the present invention means that the total viable count of the viable bacteria contained in the solid viable bacteria preparation of Bacillus coagulans isolated by the above method, which is prepared as the main pharmaceutically active ingredient, either alone or in combination, cannot be less than 1X 106CFU/g, typically 1X 107CFU/g is more than 1 multiplied by 10 at most12CFU/g or 1X 1012CFU/g is higher than the standard.
The effective dose of the present invention means that the total viable count of the viable bacteria contained in the liquid viable bacteria preparation of Bacillus coagulans isolated by the above method, which is prepared as the main pharmaceutically active ingredient, either alone or in combination, cannot be less than 1X 106CFU/mL, typically at 1X 107CFU/mL or more, up to 1 × 1012CFU/mL or 1X 1012CFU/mL or more.
The preparation provided by the invention comprises the application of the bacillus coagulans alone or in combination with other medicines, in particular the application of the bacillus coagulans alone or in combination with bifidobacteria.
The bifidobacterium of the invention refers to a living biological individual.
In the preparation for combined application of the bifidobacteria, the total viable count of the bifidobacteria contained in the solid preparation is not less than 1 x 106CFU/g, typically 1X 107CFU/g is more than 1 multiplied by 10 at most12CFU/g or 1X 1012CFU/g is above; or the liquid preparation contains Bacillus bifidus with total viable count of not less than 1 × 106CFU/mL, typically at 1X 107CFU/mL or more, up to 1 × 1012CFU/mL or 1X 1012CFU/mL or more.
The invention discloses the application of the preparation prepared by using the bacillus coagulans as a main active ingredient in preventing or treating autism for the first time, so that the application of the preparation containing the bacillus coagulans in the preparation for preventing or treating autism belongs to the protection scope of the invention.
The bacillus coagulans disclosed by the invention has the effect of preventing or treating autism when being prepared into any dosage form. If the components of the bacillus coagulans contain the bacillus coagulans component to prepare preparations, the preparations are marked on packages, specifications and the like or any other propaganda materials, and the preparations have the effect of preventing or treating the autism according to the instructions or the suggestion, the preparations fall into the protection scope of the invention.
The bacillus coagulans can be prepared into medicines, health-care foods, foods or drinks and the like.
Detailed Description
Description of the preparation examples: the preparation of the bacillus coagulans preparation has been described above, and is specifically described herein by taking bacillus coagulans TBC169 preservation number CGMCC1207 or bacillus coagulans preservation number CGMCC1.2407 (bacillus coagulans preservation number CGMCC1.2407 is purchased from the common microorganism center of the china committee for culture collection management of microorganisms) as an example, the preparation methods of other bacillus coagulans preparations are easily known by those skilled in the art through this example, and the preparation methods of other dosage forms are easily known by those skilled in the art through this example, and are not described herein. The preparation method is not limited to the examples of the invention, and any known method capable of achieving the preparation purpose can be used, and the preparation description of the examples is only illustrative of the invention and is not limiting to the protection scope of the invention.
Preparation example 1 preparation of Bacillus coagulans powder
1 preparation of fungal powder and identification of bacterial species
Sampling human excrement, soil, haystack substrate, etc., placing the samples in a sterilization bottle, taking 2g of the samples from the sterilization bottle, adding the samples into 18mL of sterilized diluent, fully mixing the samples, and performing 10 times of sterilization in a sterile operating platform-1、10-2、10-3、10-4，10-5，10-6，10-7Diluting with gradient, taking 10-5，10-6，10-7Three dilution gradients are coated on a bacillus coagulans selective single colony separation solid culture medium, the bacillus coagulans selective single colony separation solid culture medium is placed in an incubator and cultured for 48 hours at 37 ℃, and the growth vigor is selectedThe good single colony is inoculated into a bacillus coagulans liquid amplification culture medium and is subjected to amplification culture at 37 ℃ for 48 hours. The obtained culture solution was centrifuged (12000rpm) to separate the cells, and the cells were freeze-dried under vacuum to prepare dry powder of 1X 10 viable cells9And (3) more than CFU/g, identifying the strain as bacillus coagulans through physiological and biochemical analysis and 16S rRNA sequence comparison analysis, and identifying the bacillus coagulans as bacillus coagulans TBC169 with the preservation number of CGMCC 1207.
The preparation method of the bacillus coagulans powder has the preservation number of CGMCC1.2407, and comprises the steps of inoculating the bacillus coagulans powder with the preservation number of CGMCC1.2407 into a bacillus coagulans liquid amplification culture medium, and performing amplification culture at 37 ℃ for 48 hours. The obtained culture solution was centrifuged (12000rpm) to separate the cells, and the cells were freeze-dried under vacuum to prepare dry powder of 1X 10 viable cells9CFU/g is higher than the standard.
2 toxicity test
2.1 animals and 30 mice of SPF grade are selected in groups, 6-8 weeks old, the weight is 14-18g, the random groups of bacillus coagulans CGMCC1207, bacillus coagulans CGMCC1.2407 and non-administration groups are divided, and each group comprises 10 mice.
2.2 preparation of bacterial solution the different Bacillus coagulans powders were mixed with purified water to a total bacterial count of 1X 109CFU/mL of bacterial liquid.
2.3 method the same basic feed is given to each bacillus coagulans group and the group without administration, the feeding conditions are consistent, each bacillus coagulans group is irrigated with 0.5mL of bacillus coagulans liquid every day, the group without administration is irrigated with 0.5mL of purified water every day, the group is fed for 14 days, and the weight and the toxic reaction are observed.
2.4 results
All mice in each group have no abnormal condition, no tremor, spasm, dyskinesia, abnormal posture, no eyeball protrusion, normal urination, normal skin and breathing, no death condition and no toxic reaction.
3 preparing into powder
After the bacillus coagulans is separated and identified according to the steps and the method, the bacillus coagulans strain can be prepared into strain powder through experimental verification of no toxicity, and then related auxiliary materials are added according to requirements to prepare each strain powderThe seed preparation is prepared by adding starch into Bacillus coagulans powder according to the viable count of Bacillus coagulans powder to make viable count not less than 1 × 107CFU/g, and then bagging.
Application effects description of the examples:
the invention takes the preservation number of the bacillus coagulans TBC169 of CGMCC1207 or the preservation number of the bacillus coagulans of CGMCC1.2407 as a representative to show the application effect of the bacillus coagulans. The bifidobacterium used in the invention is from a commercial product, and can be any viable bifidobacterium which can be purchased by the public.
Application effects example 1: application of bacillus coagulans in treating autism
1, preparation of a model group:
1.1 the experimental animals were adult Wistar rats (purchased from the experimental animal center of vindolizhiwa): 30 adult SPF-grade Wistar female rats (with the body mass of 200-250g) and 30 male rats (with the body mass of 300-350 g). 50 male offspring rats (35 d after birth and 80-100g of body mass) are produced after the female rats and the male rats are combined.
1.2 mode of preparation referring to Schneider et al, female and male mice were housed overnight, vaginal smear was performed on the female mice the next morning, and a female patient who found a vaginal embolus was scored as day 1 of pregnancy, and pregnant female mice were individually bred. Pregnant female mice are randomly grouped according to the number of model groups and control groups which are 4:1, and on the 12.5 th day, the pregnant female mice of the model groups are injected with sodium Valproate (VPA) in one time in the abdominal cavity at the dose of 600mg/kg, and the pregnant female mice of the control groups are injected with physiological saline in the same amount in the abdominal cavity. The mice born by the pregnant mice of the model group are the autism model group, and the mice born by the pregnant mice of the control group are the control group. The day 1 after birth of the young mouse was designated as P1. Establishing a rat autism model.
1.3 the preparation result of the model group is successful in molding.
2 drug treatment experiment:
2.1 Experimental method 40 mice with autism of 35 days old (P35) and 10 mice in control group were randomly selected. Wherein the control group newborn mice are normal control group (n ═ 10), and the newborn mice of autism group are randomly divided into Bacillus coagulans group CGMCC1207, Bacillus coagulans group CGMCC1.2407, Bacillus bifidus group, and model control groupAnd 4 groups (n is 10). The treatment groups and the control group are fed with the same basic feed under the same feeding conditions, and the Bacillus coagulans group and the Bifidobacterium group have the bacteria content of 1 × 1060.5mL of CFU/mL (0.9% physiological saline is used for preparing bacterial powder) bacterial liquid is filled, and 0.5mL of 0.9% physiological saline is filled into the model control group and the control group every day for 2 weeks continuously. The effect of bacillus coagulans on the behaviourology of autistic rats was observed and compared with bifidobacteria.
2.2 behavioural assessment behavioural assessments were performed on the laboratory mice, including social interaction behavioural tests (social behavioural latency, duration, number), repetitive behavioural tests (cumulative time to reason hair) and learning memory tests (Moirrs water maze test). Selecting male mice which have the same birth time as the detection mice and the difference of the body mass less than 15g and are bred in cages as strange mice to assist in detecting social interaction behaviors. Data were statistically analyzed using SPSS 21.0.
3 results
3.1 assessment of social interaction behavior
Compared with a control group, the number of times of social behaviors of the rats with the autism model is reduced (P is less than 0.01), the social latency is increased (P is less than 0.01), the duration of the social behaviors is reduced (P is less than 0.01), and the difference has statistical significance. Compared with the autism model rat, after the bacillus coagulans CGMCC1207 and CGMCC1.2407 are treated, the frequency of social behaviors of the rat is increased (P is less than 0.05), the occurrence duration of the social behaviors is increased (P is less than 0.05), the social latency is reduced (P is less than 0.05), and the difference has statistical significance. Compared with rats in the bifidobacterium treatment group, the frequency of social behaviors of the rats in the bacillus coagulans CGMCC1207 and CGMCC1.2407 groups is increased (P < 0.05), the latency period of the social behaviors is reduced (P < 0.05), the duration of the social behaviors is increased (P < 0.05), and the difference has statistical significance. No statistical difference exists between the bacillus coagulans CGMCC1207 group and the CGMCC1.2407 group in the times of social behaviors, the appearance duration of the social behaviors and the social latency of rats (P is more than 0.05). The bacillus coagulans has a remarkable improvement effect on social behaviors of the rats with the autism and is remarkably higher than that of a bifidobacterium treatment group. See table 1.
TABLE 1 statistical score of social interaction behavior changes in rats of different groupsAnalysis of
| Group of | Number of examples | Number of times of action | Behavioral latency(s) | Duration of action(s) |
| Normal control group | 10 | 28.03±3.47 | 17.93±2.23 | 88.68±7.98 |
| Model control group | 10 | 18.77±2.16 | 32.18±3.44 | 70.62±6.23 |
| Bifidobacterium group | 10 | 21.39±2.50 | 25.85±3.36 | 73.46±4.02 |
| Coagulating spore rodBacteria CGMCC1207 group | 10 | 26.55±2.31 | 20.21±2.66 | 82.66±3.38 |
| Bacillus coagulans CGMCC1.2407 group | 10 | 26.83±2.79 | 19.87±2.56 | 82.13±4.05 |
3.2 replicate behavior assessment
Compared with a control group, the hair-organizing accumulation time of the autism model rat is increased (P is less than 0.01), and the difference has statistical significance; compared with the autism model rat, after the bacillus coagulans CGMCC1207 and CGMCC1.2407 are treated, the hair-organizing accumulation time of the rat is shortened (P is less than 0.05), and the difference has statistical significance; compared with the rats in the bifidobacterium group, the physiological hair accumulation time of the rats in the bacillus coagulans CGMCC1207 and CGMCC1.2407 groups is shortened (P is less than 0.05), and the difference has statistical significance; no statistical difference (P > 0.05) exists between the bacillus coagulans CGMCC1207 group and the CGMCC1.2407 group in the hair texture accumulation time of rats. The bacillus coagulans can obviously reduce the repeated behaviors of the rats with the autism, and the effect is obviously higher than that of the bifidobacterium. See table 2.
TABLE 2 statistical analysis of the repetitive behavioral changes in rats of different groups
| Group of | Number of examples | Accumulated time(s) for hair treatment |
| Normal control group | 10 | 67.83±11.20 |
| Model control group | 10 | 196.36±24.63 |
| Bifidobacterium group | 10 | 159.30±19.31 |
| Bacillus coagulans CGMCC1207 group | 10 | 126.98±19.76 |
| Bacillus coagulans CGMCC1.2407 group | 10 | 127.82±21.68 |
3.3 assessment of learning and memory abilities
Compared with a control group, the autism model rat has poor learning and memory ability (P is less than 0.01), and the difference has statistical significance; compared with the autism model rat, after the bacillus coagulans CGMCC1207 and CGMCC1.2407 are treated, the learning and memory ability of the rat is improved (P is less than 0.05), and the difference has statistical significance; compared with the rats in the bifidobacterium group, the rats in the bacillus coagulans group CGMCC1207 and CGMCC1.2407 have improved learning and memory abilities (P is less than 0.05), and the difference has statistical significance; no statistical difference exists between the bacillus coagulans CGMCC1207 group and the CGMCC1.2407 group in the learning and memory capacity of rats (P is more than 0.05). The bacillus coagulans can obviously improve the learning and memory ability of rats with autism, and the effect is obviously higher than that of bifidobacterium. See table 3.
TABLE 3 statistical analysis of learning and memory abilities of rats of different groups
| Group of | Number of examples | Learning memory ability(s) |
| Normal control group | 10 | 22.60±9.62 |
| Model control group | 10 | 43.35±15.55 |
| Bifidobacterium group | 10 | 37.12±13.97 |
| Bacillus coagulans CGMCC1207 group | 10 | 24.71±12.53 |
| Bacillus coagulans CGMCC1.2407 group | 10 | 24.99±11.73 |
Discussion 4
Compared with a normal control group, the autism model group has the advantages that the social behaviors are obviously reduced, the repetitive behaviors are obviously increased, the learning and memory capacity is poor, after bacillus coagulans treatment, the social behavior frequency is increased (P is less than 0.05), the social latency is reduced (P is less than 0.05), the cumulative time of the hair-care behaviors is reduced (P is less than 0.05), the learning and memory capacity is improved (P is less than 0.05), and the curative effect is obviously better than that of a bifidobacterium treatment group. The bacillus coagulans intervention can be shown to remarkably reduce the autism symptoms of the autism rats.
The bacillus coagulans preparation can effectively prevent or treat autism, obviously reduce autism symptoms, has no toxic or side effect and good application compliance, and is a new method and a new breakthrough for preventing or treating autism.
The microbial strains used in the implementation process of the invention have been preserved in the China general microbiological culture Collection center (Zhonglu of the sunny district, Beijing, China academy of sciences, microbiological research institute, zip code 100101) at 23.8.2004. And (3) classification and naming: bacillus coagulans, accession number 1207. Bacillus coagulans TBC169 deposit number CGMCC1207 is obtained by the applicant of the present invention by itself, is sold in commercial channels, and has been patented (patent number 200410098660.4). according to the provisions of the patent examination guidelines, the public can purchase or authorize the Bacillus coagulans TBC169 deposit number CGMCC1207 from commercial channels without preservation, i.e., without providing a proof of preservation, the present invention does not provide a proof of preservation of Bacillus coagulans TBC 169.
The bacillus coagulans CGMCC1.2407 is purchased from the China general microbiological culture Collection center.
Claims (8)
1. The application of the bacillus coagulans in preparing a preparation for preventing or treating autism is characterized in that the active ingredient of the preparation consists of the bacillus coagulans.
2. The use according to claim 1, wherein said formulation comprises a pharmaceutical product.
3. The use according to claim 1, wherein said Bacillus coagulans is a living organism.
4. The use as claimed in claim 1, wherein the bacillus coagulans comprises bacillus coagulans TBC169 accession number CGMCC1207 or bacillus coagulans TBC accession number CGMCC 1.2407.
5. Use according to claim 1, characterized in that autism is prevented or treated, reducing the symptoms of autism.
6. The use according to claim 1, wherein the preparation comprises a solid preparation comprising Bacillus coagulans having a viable count of not less than 1X 106CFU/g, or the liquid preparation contains Bacillus coagulans with viable count not less than 1 × 106CFU/mL。
7. Use according to claim 1, characterized in that the preparation comprises a solid preparation comprising a viable count of Bacillus coagulans, preferably 1X 107CFU/g or above, or the viable count of Bacillus coagulans contained in the liquid preparation is preferably 1 × 107CFU/mL and above.
8. Use according to claim 1, characterized in that the preparation comprises a solid preparation comprising a viable count of Bacillus coagulans, preferably 1X 1012CFU/g or above, or the viable count of Bacillus coagulans contained in the liquid preparation is preferably 1 × 1012CFU/mL and above.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611060351.7A CN106389479B (en) | 2016-11-28 | 2016-11-28 | Application of bacillus coagulans in preparation of preparation for preventing or treating autism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611060351.7A CN106389479B (en) | 2016-11-28 | 2016-11-28 | Application of bacillus coagulans in preparation of preparation for preventing or treating autism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106389479A CN106389479A (en) | 2017-02-15 |
| CN106389479B true CN106389479B (en) | 2020-03-24 |
Family
ID=58083307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611060351.7A Active CN106389479B (en) | 2016-11-28 | 2016-11-28 | Application of bacillus coagulans in preparation of preparation for preventing or treating autism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106389479B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107080755A (en) * | 2017-04-28 | 2017-08-22 | 青岛东海药业有限公司 | Application of the bacillus coagulans in prevention or treatment COPD preparation is prepared |
| CN107854495B (en) * | 2017-08-04 | 2021-04-13 | 青岛东海药业有限公司 | Application of bacillus coagulans in preparation of preparation for reducing hematuria |
| WO2019046444A2 (en) * | 2017-08-29 | 2019-03-07 | Flaask, Llc | Compositions and methods for diagnosing susceptibility to autism spectrum disorder (asd), reducing the likelihood of developing asd, and/or treating asd |
| EP3694523A4 (en) | 2017-10-13 | 2021-07-07 | Locus IP Company, LLC | Methods and substances for prevention and treatment of neurodegenerative diseases |
| CN107828705A (en) * | 2017-12-31 | 2018-03-23 | 佛山市艳晖生物科技有限公司 | One bacillus amyloliquefaciens and its application in preventing and treating autism |
| US20220015406A1 (en) * | 2019-01-25 | 2022-01-20 | Flaask, Llc | Compositions and Methods for Improving Quality of Life in Patients with Autism Spectrum Disorder |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926831A (en) * | 2006-06-26 | 2010-12-29 | 青岛东海药业有限公司 | Application of Bacillus coagulans to preparing composite preparations for preventing and treating shit odor and shit odor poisoning syndrome |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7749509B2 (en) * | 2003-08-29 | 2010-07-06 | Cobb And Company, Llp | Treatment of autism using probiotic composition |
| CN105012349A (en) * | 2015-08-06 | 2015-11-04 | 温州医科大学 | Probiotic preparation for preventing and treating vascular dementia and preparation method of probiotic preparation |
-
2016
- 2016-11-28 CN CN201611060351.7A patent/CN106389479B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926831A (en) * | 2006-06-26 | 2010-12-29 | 青岛东海药业有限公司 | Application of Bacillus coagulans to preparing composite preparations for preventing and treating shit odor and shit odor poisoning syndrome |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106389479A (en) | 2017-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106389479B (en) | Application of bacillus coagulans in preparation of preparation for preventing or treating autism | |
| CN1119154C (en) | Live triple bifidobacteria preparation and preparing method thereof | |
| CN105586299B (en) | Pro-Bionate and its application | |
| CN107854495B (en) | Application of bacillus coagulans in preparation of preparation for reducing hematuria | |
| US11376289B2 (en) | Composition and uses thereof | |
| CN106604736A (en) | Use of lactobacillus paracasei for promoting recovery of the intestinal microbiota diversity after dysbiosis | |
| JP2019526258A (en) | Leuconostoc forzapferii strain having alopecia prevention, hair growth promotion or sexual function improvement and composition containing the same | |
| CN111647526B (en) | Lactobacillus plantarum SD-H9, probiotic microbial inoculum thereof and application thereof | |
| CN103565848B (en) | Application of bacillus coagulans in preparing preparations for preventing and treating helicobacter pylori infection | |
| US20130309212A1 (en) | Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition | |
| CN105624069A (en) | Lactobacillus rhamnosus preparation and application thereof | |
| CN116121128A (en) | Bifidobacterium animalis subspecies lactis strain GOLDGUT-BB69 and application thereof | |
| CN112852670B (en) | Bifidobacterium infantis DH231 and fermentation product, application and microecological preparation thereof | |
| JP3017493B1 (en) | Autoimmune disease prevention composition | |
| KR102636571B1 (en) | Prevention and/or treatment of pneumococcal infection | |
| US20210121538A1 (en) | Interactional Biosystem | |
| WO2019227414A1 (en) | Composition and uses thereof | |
| CN116024131A (en) | Lactobacillus plantarum strain GOLDGUT-LP101 and application thereof | |
| CN115838675A (en) | Lactobacillus rhamnosus and composition and application thereof | |
| CN109394796A (en) | Lactobacillus crispatus preparation and its application | |
| JP2004135669A6 (en) | A lactic acid bacterial strain named Pediococcus pentosaceus CBT-8, which produces an antibacterial active substance that suppresses the growth of Helicobacter pylori and Listeria monocytogenes, is used as an antibacterial bacterium. Method for producing antibacterial substance having bioactive agent and method for utilizing antibacterial substance for functional foods and pharmaceuticals | |
| CN110090230B (en) | Application of bacillus coagulans in preparation of preparation for preventing or treating cholangiocarcinoma | |
| CN107115363A (en) | Application of the bacillus coagulans in prevention or treatment chronic fatigue syndrome preparation is prepared | |
| WO2019227417A1 (en) | Composition and uses thereof | |
| JP6588742B2 (en) | Immune function enhancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |